Protein delivery for retinal diseases: from basic considerations to clinical applications.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progress in retinal and eye research

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.preteyeres.2010.04.001PMID 20398784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Electroporation for Gene Transfer to Skeletal Muscles

  2012cited by this paper
• More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

  2010cited by this paper
• ADVERSE EVENTS AFTER INTRAVITREAL INFLIXIMAB (REMICADE)

  2010influential reference
• The dynamic nature of Bruch's membrane.

  2010cited by this paper
• Mixing processes in the vitreous chamber induced by eye rotations

  2010cited by this paper
• Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.

  2009cited by this paper
• Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist

  2009cited by this paper
• In vitro transscleral iontophoresis of high molecular weight neutral compounds.

  2009cited by this paper
• Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle.

  2009cited by this paper
• Effects of ciliary muscle plasmid electrotransfer of TNF-α soluble receptor variants in experimental uveitis

  2009cited by this paper
• A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

  2009influential reference
• INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS

  2009cited by this paper
• An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema

  2009cited by this paper
• Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.

  2009influential reference
• Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

  2009cited by this paper
• Preclinical Evaluation of the Novel Small-Molecule Integrin (cid:2) 5 (cid:3) 1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization

  2009cited by this paper
• New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.

  2009cited by this paper
• Protective Effect of Intravitreal Injection of Vasoactive Intestinal Peptide–Loaded Liposomes on Experimental Autoimmune Uveoretinitis

  2009cited by this paper
• Ocular gene therapy: current progress and future prospects.

  2009cited by this paper
• Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.

  2009cited by this paper
• Human transscleral albumin permeability and the effect of topographical location and donor age.

  2008cited by this paper
• Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion

  2008cited by this paper
• Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

  2008influential reference
• Subretinal bevacizumab detection after intravitreous injection in rabbits.

  2008influential reference
• CHANGES IN RETINAL SENSITIVITY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER SYSTEMIC BEVACIZUMAB (AVASTIN) THERAPY

  2008cited by this paper
• Trans-scleral Delivery of Antiangiogenic Proteins

  2008influential reference
• Drainage of Fluorescent Liposomes from the Vitreous to Cervical Lymph Nodes via Conjunctival Lymphatics

  2008cited by this paper
• Prematurely senescent ARPE-19 cells display features of age-related macular degeneration.

  2008cited by this paper
• Predicted biological activity of intravitreal VEGF Trap

  2008influential reference
• Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.

  2007cited by this paper
• Intraocular CNTF reduces vision in normal rats in a dose-dependent manner.

  2007cited by this paper
• Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.

  2007influential reference
• Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats.

  2007cited by this paper
• Effects of Nerve Growth Factor for Retinal Cell Survival in Experimental Retinal Detachment

  2007cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin).

  2007influential reference
• Molecular and cellular alterations induced by sustained expression of ciliary neurotrophic factor in a mouse model of retinitis pigmentosa.

  2007cited by this paper
• Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging.

  2007influential reference
• Intravitreal injection of ciliary neurotrophic factor (CNTF) causes peripheral remodeling and does not prevent photoreceptor loss in canine RPGR mutant retina.

  2007cited by this paper
• Protein kinase Czeta (PKCzeta) regulates ocular inflammation and apoptosis in endotoxin-induced uveitis (EIU): signaling molecules involved in EIU resolution by PKCzeta inhibitor and interleukin-13.

  2007cited by this paper
• Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy

  2007cited by this paper
• Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres.

  2007cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2007cited by this paper
• RITUXIMAB PENETRATES FULL-THICKNESS RETINA IN CONTRAST TO TISSUE PLASMINOGEN ACTIVATOR CONTROL

  2007influential reference
• Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

  2007cited by this paper
• Transport Barriers in Transscleral Drug Delivery for Retinal Diseases

  2007influential reference
• Intravitreal Toxicity of High-Dose Etanercept

  2007influential reference
• Placental growth factor-1 and epithelial haemato–retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy

  2007cited by this paper
• Evaluation of the Vascular Targeting Agent Combretastatin A-4 Prodrug on Retinal Neovascularization in the Galactose-Fed Dog

  2007cited by this paper
• TUMOR NECROSIS FACTOR ANTAGONISTS: Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation

  2007influential reference
• Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.

  2007cited by this paper
• Protein Kinase C (cid:1) (PKC (cid:1) ) Regulates Ocular Inflammation and Apoptosis in Endotoxin-Induced Uveitis (EIU) Signaling Molecules Involved in EIU Resolution by PKC (cid:1) Inhibitor and Interleukin-13

  2007cited by this paper
• Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats

  2007cited by this paper
• Pharmacokinetics of intravitreal ranibizumab (Lucentis).

  2007influential reference
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• Application of encapsulated cell technology for retinal degenerative diseases.

  2006cited by this paper
• A study of retinal penetration of intravitreal tenecteplase in pigs.

  2006influential reference
• Human scleral hydraulic conductivity: age-related changes, topographical variation, and potential scleral outflow facility.

  2006cited by this paper
• Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment.

  2006cited by this paper
• Pigment epithelium‐derived factor (PEDF) is an endogenous antiinflammatory factor

  2006cited by this paper
• A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

  2006cited by this paper
• Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF‐α soluble receptor in uveitis

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)

  2006influential reference
• Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer

  2006cited by this paper
• Intraocular implants for extended drug delivery: therapeutic applications.

  2006cited by this paper
• Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis

  2006cited by this paper
• ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study

  2006influential reference
• AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells

  2006cited by this paper
• Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa.

  2006cited by this paper
• CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina.

  2006cited by this paper
• Adalimumab in the therapy of uveitis in childhood

  2006cited by this paper
• Study of the influence of angiostatin intravitreal injection on vascular leakage in retina and iris of the experimental diabetic rats.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

  2006cited by this paper
• Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants.

  2006cited by this paper
• Application of encapsulated cell technology for retinal degenerative diseases

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab

  2006cited by this paper
• Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats.

  2005cited by this paper
• Anti-TNF-α therapy for sight threatening uveitis

  2005cited by this paper
• Ocular rigidity in living human eyes.

  2005cited by this paper
• Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.

  2005cited by this paper
• Applications of liposomes in ophthalmology.

  2005cited by this paper
• Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

  2005cited by this paper
• Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse.

  2005cited by this paper
• Topically applied antibody fragments penetrate into the back of the rabbit eye

  2005cited by this paper
• Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain.

  2005cited by this paper
• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  2005cited by this paper
• Study of Ocular Transport of Drugs Released from an Intravitreal Implant Using Magnetic Resonance Imaging

  2005cited by this paper
• Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant.

  2005cited by this paper
• VEGF Inhibition Study in Ocular Neovascularization (VISION): Second Year Efficacy Data

  2005cited by this paper
• Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis.

  2005cited by this paper
• Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

  2005influential reference
• Cell culture models of the ocular barriers.

  2005cited by this paper
• Tetracycline-Inducible Viral Interleukin-10 Intraocular Gene Transfer, Using Adeno-Associated Virus in Experimental Autoimmune Uveoretinitis

  2005cited by this paper
• Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium.

  2005cited by this paper

• Nucleic acid drug delivery in ophthalmology: Emerging trends and future perspectives.

  2026cites this paper
• Nanotechnology Strategies for Ocular Reactive Oxygen Species Regulation and Functional Contact Lens Platforms

  2026cites this paper
• Protein delivery to the eye: assessing therapeutic potential across inner and outer retina.

  2026cites this paper
• Advances in Ocular Implants: From Geometry Design to Controlled Drug Release Mechanisms.

  2026cites this paper
• Mucoadhesive Tannic Acid-Cross-Linked Nanogels for Reactive Oxygen Species Scavenging and Enhanced Ocular Therapeutic Delivery.

  2025cites this paper
• Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

  2025cites this paper
• Safety and biocompatibility of a novel biodegradable aflibercept-drug delivery system in rhesus macaques

  2025influential citation
• Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression.

  2025cites this paper
• Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges

  2025cites this paper
• Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases

  2025cites this paper
• The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina

  2024cites this paper
• Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer.

  2024cites this paper
• Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders

  2024cites this paper
• Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives

  2024cites this paper
• Insights into ocular therapeutics: a comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery

  2024cites this paper
• Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model

  2023cites this paper
• Lipid-based nanocarriers challenging the ocular biological barriers: Current paradigm and future perspectives.

  2023cites this paper
• The Design and Developments of Protein‐Polysaccharide Biomaterials for Corneal Tissue Engineering

  2023cites this paper
• Polymer- and Lipid-Based Nanocarriers for Ocular Drug Delivery: Current Status and Future Perspectives.

  2023cites this paper
• Combined Anti-Angiogenic and Anti-Inflammatory Nanoformulation for Effective Treatment of Ocular Vascular Diseases

  2023cites this paper
• Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration

  2023cites this paper
• Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.

  2022cites this paper
• Promising Role of Silk-Based Biomaterials for Ocular-Based Drug Delivery and Tissue Engineering

  2022cites this paper
• Recombinant protein delivery enables modulation of the phototransduction cascade in mouse retina

  2022cites this paper
• Ocular Barriers and Their Influence on Gene Therapy Products Delivery

  2022cites this paper
• Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System

  2022cites this paper
• Visualizing spatial differences in corneal electroretinogram potentials using a three-dimensional surface spline

  2021cites this paper
• Gene Therapy for Uveitis

  2021cites this paper
• Intravitreal hydrogels for sustained release of therapeutic proteins.

  2020cites this paper
• Retinal and choroidal cancers: Blood-retinal barriers considerations in ocular chemotherapy

  2020cites this paper
• Characterization, Stability, and In Vivo Efficacy Studies of Recombinant Human CNTF and Its Permeation into the Neural Retina in Ex Vivo Organotypic Retinal Explant Culture Models

  2020cites this paper
• Autophagy modulation in animal models of corneal diseases: a systematic review

  2020cites this paper
• Injectable in-situ gel depot system for targeted delivery of biologics to the retina

  2020cites this paper
• Transferrin Non-Viral Gene Therapy for Treatment of Retinal Degeneration

  2020cites this paper
• [Anti-TNF-α in the treatment of non-infectious uveitis].

  2020cites this paper
• Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration

  2020cites this paper
• Teaser Hydrogels providing sustained delivery of biologics to the back of the eye can make a significant impact in the treatment of many ocular diseases

  2019cites this paper
• Effects of Exogenous Neuroglobin (Ngb) on retinal inflammatory chemokines and microglia in a rat model of transient hypoxia

  2019cites this paper
• Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab

  2019cites this paper
• Recent advances in slow and sustained drug release for retina drug delivery

  2019cites this paper
• Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives.

  2019cites this paper
• Hydrogels for sustained delivery of biologics to the back of the eye.

  2019cites this paper
• Electrostatic complex of neurotrophin 4 with dendrimer nanoparticles: controlled release of protein in vitro and in vivo

  2019cites this paper
• Non‐viral ocular gene therapy, pEYS606, for the treatment of non‐infectious uveitis: Preclinical evaluation of the medicinal product

  2018cites this paper
• Controlled release technology for anti‐angiogenesis treatment of posterior eye diseases: Current status and challenges

  2018cites this paper
• Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro

  2018cites this paper
• Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina.

  2017cites this paper
• Ultrasound‐mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection

  2017cites this paper
• Peptide and Protein-Based Therapeutic Agents

  2017cites this paper
• Hydrogel Formulations for Ophthalmic Delivery

  2017cites this paper
• Optimisation of HPMC ophthalmic inserts with sustained release properties as a carrier for thermolabile therapeutics.

  2017cites this paper
• Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins.

  2017cites this paper
• Mathematical and numerical methods for modeling drug delivery to the posterior segment of the eye

  2017cites this paper
• Long Term Ocular Drug Delivery with Novel Pentablock Copolymers; Part I: Composite Nanoformulation of Macromolecules For Back of the Eye Diseases, Part II: Dexamethasone Nanoparticle to Develop an In Vitro Model for Glaucoma

  2017cites this paper
• Conventional and Advanced Ocular Formulation and Delivery: A Mini Review

  2017cites this paper
• Dosage forms in therapy of posterior segments of the eye

  2016cites this paper
• Intravitreal Injection of Proinsulin-Loaded Microspheres Delays Photoreceptor Cell Death and Vision Loss in the rd10 Mouse Model of Retinitis Pigmentosa.

  2016cites this paper
• Ocular Delivery of Proteins and Peptides

  2016cites this paper
• Hydrogel for Simultaneous Tunable Growth Factor Delivery and Enhanced Viability of Encapsulated Cells in Vitro.

  2016cites this paper
• A flexible device for ocular iontophoretic drug delivery.

  2016cites this paper
• Mathematical assessment of drug build-up in the posterior eye following transscleral delivery

  2016cites this paper
• Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery.

  2015influential citation
• Affinity Release of Insulin-like Growth Factor-1 Increases the Viability of Retinal Pigment Epithelium Cells In Vitro

  2015cites this paper
• Iontophoresis as a non-invasive enhancement technique for the administration of drugs across biological membranes

  2015cites this paper
• The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development.

  2015cites this paper
• Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye

  2015cites this paper
• Subconjunctival Injection of XG-102, a c-Jun N-Terminal Kinase Inhibitor Peptide, in the Treatment of Endotoxin-Induced Uveitis in Rats

  2015cites this paper
• Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.

  2015cites this paper
• Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers.

  2015cites this paper
• Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update.

  2015cites this paper
• Antibody therapies and their challenges in the treatment of age-related macular degeneration.

  2015cites this paper
• In vitro permeability of a model protein across ocular tissues and effect of iontophoresis on the transscleral delivery.

  2014cites this paper
• A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles.

  2014cites this paper
• A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation

  2014cites this paper
• Microneedle Delivery of Ophthalmic Macromolecules

  2014cites this paper
• Bispecific therapeutics for ophthalmic indications: target selection and the optimal molecular format

  2014cites this paper
• A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.

  2014cites this paper
• Recent developments in the treatment of age-related macular degeneration.

  2014cites this paper
• The Future of Vitrectomy

  2014influential citation
• Ocular Delivery of Biopharmaceuticals

  2014cites this paper
• Dendrimers for gene delivery – a potential approach for ocular therapy?

  2014cites this paper
• A critical assessment of in vitro tissue models for ADME and drug delivery.

  2014cites this paper
• Ocular delivery of macromolecules.

  2014cites this paper
• V.B.3. The Future of Vitrectomy

  2014cites this paper
• Chitosan and Chitosan Derivatives for Mucosal Delivery of Biopharmaceutical Drugs

  2013cites this paper
• DEVELOPMENTS AND ADVANCED APPROACHES OF OPHTHALMIC DRUG DELIVERY SYSTEM: A REVIEW

  2013cites this paper
• Decrease of ATP by mitochondrial m-calpain inhibitory peptide in the rat retinas.

  2013cites this paper
• Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization

  2013cites this paper
• Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration.

  2013cites this paper
• Sustained Delivery of Biologics to Back of the Eye

  2013cites this paper
• Chapter 38 – Drug Delivery

  2013cites this paper
• ISSN: 2249-0337 Review Article Current Trends Towards an Ocular Drug Delivery System: Review

  2013cites this paper
• Nanoparticles for Ocular Drug Delivery

  2013cites this paper
• Etude de la toxicité et des mécanismes de mort cellulaire induits par les glucocorticoïdes sur les cellules endothéliales

  2013cites this paper
• Current Trends Towards an Ocular Drug Delivery System: Review

  2013cites this paper
• Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases.

  2012cites this paper
• Pigment Epithelium-Derived Factor Released by Müller Glial Cells Exerts Neuroprotective Effects on Retinal Ganglion Cells

  2012cites this paper
• Drug delivery to the eye: current trends and future perspectives.

  2012cites this paper
• Aqueous Humor and Plasma Adiponectin Levels in Proliferative Diabetic Retinopathy Patients

  2012cites this paper
• Influence of molecular shape, conformability, net surface charge, and tissue interaction on transscleral macromolecular diffusion.

  2012cites this paper